| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| IDEAYA Biosciences Inc. | Darovasertib - (IDE196-009) | Uveal Melanoma | Phase 2 | Data Released | Oral | Oncology |
| IDEAYA Biosciences Inc. | IDE397 and Trodelvy | Solid Tumors | Phase 2 | Data Released | IDE397 oral Trodelvy intravenous | Oncology |
| IDEAYA Biosciences Inc. | Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM) | Ocular Melanoma | Phase 2 | Data Released | Oral | Oncology |
| ImageneBio Inc. | IMG-007 - (ADAPTIVE) | Atopic dermatitis and other immunological diseases | Phase 2b | Ongoing | intravitreal | Immunology |
| Immatics N.V. | Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME) | Melanoma | Phase 3 | Data Released | Intravenous | Oncology |
| Immatics N.V. | Anzu-cel (anzutresgene autoleucel, IMA203) (ACTengine) - (SUPRAME) | Melanoma | Phase 3 | Data Released | Intravenous | Oncology |
| Immuneering Corporation | Atebimetinib (IMM-1-104) + mGnP | Solid tumors, pancreatic cancer, melanoma | Phase 2a | Data Released | oral | Oncology |
| Immuneering Corporation | Atebimetinib (IMM-1-104) + mGnP | Solid tumors, pancreatic cancer, melanoma | Phase 2a | Data Released | oral | Oncology |